Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
No significant clinical drug-drug interaction potential with indacaterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Once-daily administration of indacaterol does not induce tachyphylaxis in vivo Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010